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Abstract
Objective: Obesity is very common in patients with obstructive sleep apnoea (OSA) and polycystic ovary syndrome (PCOS). 
Longitudinal studies assessing OSA risk in PCOS and examining the role of obesity are lacking. Our objective was to assess 
the risk of OSA in women with vs without PCOS and to examine the role of obesity in the observed findings.
Design: Population-based retrospective cohort study utilizing The Health Improvement Network (THIN), UK.
Methods: 76 978 women with PCOS and 143 077 age-, BMI- and location-matched women without PCOS between 
January 2000 and May 2017 were identified. Hazard ratio (HR) for OSA among women with and without PCOS were 
calculated after controlling for confounding variables using multivariate Cox models.
Results: Median patient age was 30 (IQR: 25–35) years; median follow-up was 3.5 (IQR: 1.4–7.1) years. We found 298 
OSA cases in PCOS women vs 222 in controls, with incidence rates for OSA of 8.1 and 3.3 per 10 000 person years, 
respectively. Women with PCOS were at increased risk of developing OSA (adjusted HR = 2.26, 95% CI: 1.89–2.69, 
P < 0.001), with similar HRs for normal weight, overweight and obese PCOS women.
Conclusions: Women with PCOS are at increased risk of developing OSA compared to control women irrespective of 
obesity. Considering the significant metabolic morbidity associated with OSA, clinicians should have a low threshold to 
test for OSA in women with PCOS. Whether OSA treatment has an impact on PCOS symptoms and outcomes needs to be 
examined.
Introduction
Polycystic ovary syndrome (PCOS) is the commonest 
endocrine disorder in women of reproductive age 
(prevalence 8–13%) (1). Chronic anovulation, 
hyperandrogenism and ovarian polycystic morphology 
are the defining features of PCOS.
PCOS is associated with multiple comorbidities 
including obesity, insulin resistance (IR), dyslipidaemia, 
gestational diabetes (GDM), type 2 diabetes (T2D), 
hypertension, non-alcoholic fatty liver disease, impaired 
quality of life (QOL), cardiovascular disease (CVD) 
and mortality amongst others (2, 3, 4). Weight loss 
(by lifestyle intervention or bariatric surgery) remains 
the only specific treatment for PCOS. The remaining 
treatments are mainly symptomatic (oral contraceptives 
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for irregular periods, anti-androgens for hirsutism, 
ovulation induction for infertility) (5). Hence, there is 
a need for better understanding of the pathogenesis of 
PCOS-related metabolic risk and comorbidities in order to 
develop effective therapies (6).
Obstructive sleep apnoea (OSA) is common, affecting 
17–26% of men and 9–28% of women; the prevalence 
being lower in women of reproductive age compared 
to men (7). OSA is characterized by instability in the 
upper airways during sleep, leading to recurrent upper 
airway obstructions, sleep architecture disruption 
and cyclical changes in heart rate, blood pressure, 
sympathetic activity, intrathoracic pressure and oxygen 
saturations (7, 8). Obesity is very common in patients 
with OSA and PCOS (9). In addition, OSA is associated 
with similar comorbidities to PCOS, such as IR, GDM, 
T2D, hypertension, impaired QOL, CVD and mortality 
(7, 10). Hence, it is plausible that OSA and PCOS might 
co-exist and that either condition could contribute to the 
comorbidities of the other (9). This is further supported 
by a recent systematic review that showed that OSA 
prevalence in women with PCOS was 32% (95% CI: 
13–55%) (11). However, these studies were of small size 
(n < 60), at risk of selection bias and cross-sectional design, 
barring the determination of the direction of relationship. 
Additionally, the study populations exclusively comprised 
patients with grade II obesity or higher. Hence, there is a 
need to examine the relationship between OSA and PCOS 
in a longitudinal population-based study, which allows to 
assess the impact of obesity.
Several mechanisms, other than obesity and insulin 
resistance, might increase the likelihood of OSA in 
women with PCOS compared to women without PCOS 
of similar adiposity including hyperandrogenism, 
low progesterone (due to anovulation) and increased 
oxidative stress (9).
We hypothesized that women with PCOS are at 
increased risk of developing OSA compared to women 
without PCOS regardless of the degree of obesity. The 
primary aim of this study was to assess the risk of incident 
OSA in women with PCOS vs women without PCOS and 
examine the role of obesity in the observed relationships. 
A secondary aim was to assess predictors of incident OSA 
in women with PCOS.
Subjects and methods
For full description of the methods please refer to the 
online supplement.
Ethics statement
The use of THIN data for research was approved by the 
South-East Multicenter Research Ethics Committee in 
2003 without the need for informed consent. As per 
requirement of the ethical approval, further registration 
and authorization for this project were obtained from the 
relevant Scientific Review Committee (17THIN026).
Study design and setting
We conducted a matched-controlled retrospective cohort 
study using data from UK general practices contributing 
to The Health Improvement Network (THIN) electronic 
database, as we have in previous studies (2, 12, 13).
Study population
The open cohort extended from the 1st January 2000 
(study start date) to the 15th May 2017 (study end date).
Inclusion criteria: All women who were aged 
18–50  years at the index date (study entry) and had a 
documentation of PCOS at any time during the study 
period were included in the exposed group. Patients with 
any documentation of OSA prior to the index date were 
excluded. Women without documented PCOS at any time 
during the study period were included in the unexposed 
(control) arm. The index date was defined as the date of 
first documentation of PCOS for newly diagnosed cases 
and from the date patient became eligible if the first 
documentation of PCOS was prior to the eligibility date 
(for existing cases) (Supplementary Fig. E1, see section on 
supplementary data given at the end of this article).
Each exposed patient was randomly matched to two 
unexposed patients (1:2 ratio) for general practice, age at 
index date and BMI (14, 15).
To minimize the immortal time bias, each randomly 
matched eligible unexposed patient was assigned the 
same index date as their corresponding exposed patient 
(16). Follow-up end date (exit date) was determined from 
the earliest occurrence of the first documentation of OSA, 
transfer to another practice, death or study end.
Selection of Read Codes and PCOS definition
Read Codes to define PCOS, OSA and covariates were 
compiled using a methodical Read Code search strategy 
(see Supplementary Panel E1 and Table  E1) Since there 
is a possibility of misclassification between PCOS and 
polycystic ovaries (PCO) due to the resemblance of codes 
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during data entry, they have been combined in prevalence 
studies using general practice electronic databases (17).
Statistical analysis
Potential confounders and covariates were chosen based 
on biological plausibility and links to the exposure and 
outcome of interest (PCOS and OSA respectively). These 
included age, Townsend social deprivation index (14), 
BMI, smoking status, diabetes mellitus, impaired glucose 
regulation (18), hypertension (19), hypothyroidism, 
antiandrogen medication and metformin. The critical 
value for statistical significance was set at 5% and 95% 
confidence intervals were used in the population estimate 
of hazard ratios. Further analysis included calculating the 
number and percentage of incident cases, person years 
and incidence rates. Unadjusted and adjusted hazard 
ratios were estimated using Cox regression models.
Sensitivity analysis was carried out to assess selection 
bias due to case definition (PCOS and PCO vs PCOS only) 
and survival bias due to inclusion of prevalent cases 
(who had the documentation of PCOS prior to becoming 
eligible for the study) (20). In the primary analysis, we did 
not consider ethnicity as a covariate due to high missing 
values (48.9%). In a sensitivity analysis we assigned 
a separate ethnicity category for missing values and 
included into the Cox model as an additional covariate.
Another model confined to PCOS cases (excluding 
controls) was used to assess the association of PCOS 
with OSA while considering PCOS phenotypes and 
antiandrogen medication as covariates. STATA MP version 
14.2 was used for data cleaning and analysis (21).
Results
Study population characteristics
The study population included 76 978 women with PCOS 
and 143 077 matched control women from 763 general 
practices registered with THIN (Fig.  1). The median 
follow-up was 3.5  years (IQR: 1.38 to 7.14) with no 
significant difference between women with and without 
PCOS (Fig. 1). There was no obvious difference between 
women with and without PCOS with regards to age 
(median 30 years, IQR: 25–35), Townsend index for social 
deprivation, BMI and smoking status (Table  1). When 
compared to controls, women with PCOS were more likely 
to have T2D (2.2 vs 1.0%), hypertension (3.0 vs 2.0%), 
hypothyroidism (3.9 vs 2.3%) and impaired glucose 
regulation (0.6% vs 0.3%) (Table 1). The PCOS group was 
also more likely to develop diabetes mellitus during the 
follow-up when compared to control group (5.6 vs 2.6%).
The clinical features of PCOS and medications used in 
the study cohort are summarized in Table 2. Of the 76 978 
women with PCOS, 22  307 (29.0%) were defined using 
PCOS Read Code while the remainder were defined using 
PCO Read Code (see Supplementary Table E1).
Primary analysis
There were 298 incident cases of OSA among 76  978 
women with PCOS and 222 among 143  077 women 
without PCOS. Incidence of OSA was significantly higher 
in women with PCOS vs the matched controls (8.1 vs 
3.3 per 10  000 person-years of follow-up, P < 0.0001) 
(Table  3). Women with PCOS had an increased hazard 
of developing OSA when compared to their matched 
Figure 1
Selection of patients with polycystic ovary syndrome (PCOS) 
and controls. A total of 14 417 129 patients were registered 
with 763 eligible practices during 2000 to 2017. Of these, 
2 803 607 women were of 18 to 50 years old and were eligible. 
According to the criteria indicated in ‘methods’ section, there 
were 76 978 women with PCOS in PCOS cohort. The control 
cohort had 143 077 women who were matched within same 
general practice for age and BMI at a ratio of 1:2. There were 
298 and 222 incident cases of sleep apnoea in PCOS and 
control cohorts respectively.
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controls (HR = 2.46, 95% CI: 2.07–2.93, P < 0.001). Women 
with PCOS remained at increased risk of developing OSA 
compared to women without PCOS following adjustment 
for age, Townsend score, BMI, hypothyroidism at baseline, 
baseline and incident diabetes/IGR (adjusted HR = 2.26, 
95% CI: 1.89 to 2.69, P < 0.001) (Table 3).
In addition to PCOS, we identified older age, 
increasing BMI and the presence of hypothyroidism at 
baseline as independent predictors of incident OSA (see 
Supplementary Table E2).
Sensitivity analysis
Limiting the analysis to incident cases of PCOS (adjusted 
HR = 2.20, 95% CI: 1.58–3.06, P < 0.001) or PCOS Read 
Codes only (adjusted HR = 2.93, 95% CI: 2.15–3.99, 
P < 0.001) resulted in similar point estimates to those found 
in the analysis of the whole study population (Table  3). 
Adding ethnicity as an additional covariate did not alter our 
findings (adjusted HR 2.21, 95% CI: 1.85–2.64, P < 0.001).
Analysis to assess if risk of OSA among women 
with PCOS is independent of BMI
Increasing BMI was associated with increasing OSA 
incidence in women with and without PCOS, but the HRs 
were greater in women with PCOS vs control in all BMI 
categories (see Fig. 2 and Supplementary Table E2). When 
compared to women without PCOS, women with PCOS 
showed a higher risk (adjusted HR (95% CI)) of developing 
OSA in all three BMI (kg/m2) categories (BMI <25: 1.91 
(0.92–3.97), P = 0.081; BMI 25–29.99: 2.25 (1.33–3.81), 
P = 0.003; BMI ≥30: 2.10 (1.72–2.56), P < 0.001) (see Fig. 2 
and Supplementary Table E3).
Analysis to assess the role of factors other than 
BMI in OSA among PCOS women
In addition to older age, increasing BMI and presence 
of hypothyroidism, we identified anovulation (adjusted 
HR (95% CI) 1.33 (1.05–1.69), P = 0.02), hirsutism 
Table 1 Baseline characteristics of women with PCOS and control women without PCOS.
Characteristics With PCOS (n = 76 978) Without PCOS (n = 143 077)
Age (years; mean (s.d.)) 30.2 (7.4) 30.4 (7.3)
Townsend score*
 1 13 865 (18.0%) 25 951 (18.1%)
 2 12 716 (16.5%) 23 910 (16.7%)
 3 15 072 (19.6%) 28 172 (19.7%)
 4 14 498 (18.8%) 27 341 (19.1%)
 5 10 223 (13.3%) 19 675 (13.8%)
Missing data 10 604 (13.8%) 18 028 (12.6%)
BMI (kg/m2; mean (s.d.) 28.6 (7.6) 27.4 (6.4)
BMI categorized
 <25 kg/m2 25 739 (33.4%) 52 666 (36.8%)
 25–29.99 kg/m2 15 065 (19.6%) 29 682 (20.8%)
 ≥30 kg/m2 24 139 (31.4%) 37 585 (26.3%)
 Missing or implausible data 12 035 (15.6%) 23 144 (16.2%)
Smoking status
 Non-smokers 56 105 (72.9%) 101 370 (70.8%)
 Smokers 17 383 (22.6%) 32 778 (22.9%)
 Missing or implausible data 3490 (4.5%) 8929 (6.2%)
Medical conditions at baseline
 Diabetes 1694 (2.2%) 1449 (1.0%)
 Hypertension 2325 (3.0%) 2805 (2.0%)
 Hypothyroidism 2987 (3.9%) 3228 (2.3%)
 Impaired glucose regulation† 446 (0.6%) 368 (0.3%)
Ethnicity
 Caucasian-European 36 670 (47.6%) 58 182 (40.7%)
 Black-Afro-Caribbean 1692 (2.2%) 3222 (2.3%)
 South Asians 3929 (5.1%) 4266 (3.0%)
 Others including Chinese, Middle-Eastern 1013 (1.3%) 1781 (1.2%)
 Mixed-race 715 (0.9%) 1008 (0.7%)
 Missing (no codes found in Medical or AHD file) 32 959 (42.8%) 74 618 (52.2%)
*Townsend score – presented as quintiles with 1 least deprived and 5 most deprived. †(Includes impaired fasting glucose and impaired glucose 
tolerance).
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(1.37 (1.05–1.80), P = 0.02) and treatment with metformin 
(1.69, 1.28–2.22, P < 0.001) as predictors of incident 
OSA (Table 4).
Discussion
This is the first large longitudinal study assessing the 
temporal relationship between PCOS and OSA in a 
European population and that accounted for the role 
of obesity and adjusted for a large number of potential 
confounders. We found that women with PCOS were 
at increased risk of developing OSA compared women 
without PCOS regardless of the severity of obesity and 
independent of a wide range of potential confounders. 
We also found that hirsutism and chronic anovulation, 
clinical features of androgen excess, which is closely 
linked to insulin resistance in the context of PCOS, were 
independent predictors of OSA development in women 
with PCOS.
A recent study from Taiwan also found an increase 
OSA incidence in women with PCOS, but was of much 
smaller sample size (n = 9190 vs 220 055) and did not match 
for BMI; in addition, the adjustment for confounders 
was limited and did not explore the possible underlying 
mechanisms (22).
The prevalence of OSA in women with PCOS has been 
investigated in several small-scale cross-sectional studies 
(9). Two recent meta-analyses showed an estimated OSA 
prevalence (based on polysomnography or portable level 
II devices) of 36.1% (95% CI: 22.4–51.0%) and 32% (95% 
CI: 13–55%) in women with PCOS (23, 24). However, the 
prevalence of OSA in women with PCOS varied widely 
from 0 to 69% (9). This big variation in OSA prevalence 
Table 3 Risk of women with PCOS developing OSA compared to women without PCOS.
Primary analysis Sensitivity analysis (incident cases)
Sensitivity analysis (PCOS specific 
Read Codes only)
Exposed Unexposed Exposed Unexposed Exposed Unexposed
Total number of patients 76 978 143 077 23 349 43 106 24 603 44 991
Incident OSA n (%) 298 (0.39) 222 (0.16) 86 (0.37) 60 (0.14) 115 (0.47) 63 (0.14)
Person years 368 203 680 011 112 290 193 646 107 959 187 801
Incidence rates per 10 000 
person years
8.1 3.3 7.7 3.1 10.7 3.4
Hazard ratio (95% CI) 2.46 (2.07–2.93) 2.44 (1.76–3.40) 3.11 (2.29–4.23)
 P-value <0.001 <0.001 <0.001
Adjusted hazard ratio (95% CI)* 2.26 (1.89–2.69) 2.20 (1.58–3.06) 2.93 (2.15–3.99)
 P-value <0.001 <0.001 <0.001
Adjusted hazard ratio (95% CI)† 2.23 (1.87–2.66) 2.14 (1.53–2.99) 2.87 (2.10–3.92)
 P-value <0.001 <0.001 <0.001
*Adjusted for age, Townsend score, BMI, diabetes or impaired glucose regulation at baseline and hypothyroidism at baseline. †Adjusted for age, 
Townsend score, BMI, diabetes or impaired glucose regulation up to end of follow-up and hypothyroidism at baseline.
Table 2 PCOS diagnostic features and use of medication. Data are presented as n (%)
Characteristics With PCOS (n = 76 978) Without PCOS (n = 143 077)
PCOS features at baseline
 Anovulation 20 106 (26.1) 10 463 (7.3)
 Any clinical androgen excess feature 21 974 (28.6) 23 231 (16.3)
  Acne 14 589 (19.0) 19 371 (13.5)
  Alopecia 2749 (3.6) 3820 (2.7)
  Hirsutism 7748 (10.1) 1269 (0.9)
 Polycystic ovaries 58 099 (75.5) 0 (0)
Medications
 Oral Contraceptive Pill (OCP) including an anti-androgenic 
progestin component*
22 798 (29.6) 17 005 (11.9)
 Cyproterone 17 346 (22.5) 9381 (6.6)
 Drospirenone 9685 (12.6) 10 280 (7.2)
 Other antiandrogen 192 (0.2) 14 (0.0)
 Metformin 18 571 (24.1) 2925 (2.0)
*Use of either cyproterone acetate or drospirenone. Since some patients were prescribed both cyproterone and drospirenone during the period 
covered, the number of OCP users is slightly smaller than the arithmetic sum of the numbers of cyproterone and drospirenone users.
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between studies is attributed to multiple factors, including 
the application of different AHI cut-offs to diagnose OSA, 
small sample sizes, variation in obesity prevalence and 
potential selection bias due to recruitment from specialized 
clinics, raising the possibility that the results many not 
be generalizable (9). Our current study addresses many of 
these gaps by conducting a population-based longitudinal 
study of a large sample size that included patients with 
normal, overweight and obese BMI categories. The impact 
of PCOS on risk of OSA was stronger in overweight than 
in obese women; however, this needs to be interpreted 
with caution given the confidence intervals of effect 
sizes overlap.
The cross-sectional studies that showed low 
prevalence rates of OSA in women with PCOS were 
mainly carried out in leaner cohorts, hence suggesting 
that the high prevalence of OSA in women with PCOS was 
only applicable to women with obesity. Whether women 
with PCOS were truly at increased risk of OSA compared 
to women with similar obesity but without PCOS was 
unclear (9, 23, 24). Our study addressed this limitation 
of earlier studies by including a control group of women 
matched for BMI amongst other important covariates, 
and our results show clearly that women with PCOS were 
at increased risk OSA compared to women without PCOS. 
In addition, we have shown that this increased risk of OSA 
in women with PCOS was evident irrespective of whether 
patients were normal weight, overweight or have obesity. 
However, the observed relationships were stronger in 
women who were overweight or had obesity.
Several mechanisms might explain the link between 
PCOS and OSA and explain the findings of this study 
(9, 25). Androgen excess is a cardinal feature of PCOS 
and androgens are implicated in the pathogenesis of 
OSA as they affect upper airway stability and ventilatory 
drive (9). OSA is consistently more common in men than 
women (26, 27), which may also point to androgens 
as a contributing factor. Our data support this notion 
as a documented diagnosis of hirsutism, a clinical 
manifestation of androgen excess, was an independent 
predictor of incident OSA. In addition to androgen 
excess, oxidative stress and low progesterone might play a 
role in the observed relationship between PCOS and OSA 
(25). Oxidative stress can contribute to the pathogenesis 
of OSA by causing dysfunction in the carotid body 
chemoreceptors resulting in ventilatory instability (28). 
Progesterone is a respiratory stimulant and can result in 
lowering upper respiratory resistance (29). Furthermore, 
OSA is associated with lower progesterone in women (30) 
and low progesterone affects the ventilatory drive (9, 31, 
32). Our results also support this potential mechanism as 
anovulation predicted incident OSA. Insulin resistance, 
a feature of OSA and a predictor of incident apnoea can 
also contribute to the observed relationships in this 
study (33, 34).
OSA is associated with multiple comorbidities 
including road traffic accidents, hypertension, T2D, CVD, 






Age 1.06 (1.04–1.07) <0.001
Townsend
 1 1.00 (Reference level)
 2 1.26 (0.83–1.89) 0.27
 3 1.41 (0.95–2.08) 0.08
 4 1.58 (1.07–2.33) 0.02
 5 1.67 (1.10–2.53) 0.02
Missing 1.23 (0.77–1.97) 0.38
BMI category
 <25 kg/m2 1.00 (Reference level)
 25–29.99 kg/m2 3.01 (1.60–5.69) 0.001
 ≥30 kg/m2 12.50 (7.24–21.58) <0.001
 Missing 3.64 (1.91–6.95) <0.001
Diabetes or IGR* 0.72 (0.44–1.18) 0.19
Hypothyroidism 1.76 (1.20–2.58) 0.004
Anovulation 1.33 (1.05–1.69) 0.02
 Androgen excess features
  Hirsutism 1.37 (1.05–1.80) 0.02
  Acne 0.85 (0.61–1.19) 0.35
  Alopecia 0.97 (0.64–1.46) 0.89
 Metformin 1.69 (1.28–2.22) <0.001
  Antiandrogen drug 0.77 (0.57–1.05) 0.10
*Impaired glucose response (includes impaired fasting glucose and 
impaired glucose tolerance). Values in boldface indicate statistical 
significance.
Figure 2
Impact of BMI on the hazard of obstructive sleep apnoea 
(OSA). Women in both PCOS and control cohorts were 
subcategorized into lean, overweight and obese groups. The 
hazard of developing OSA among PCOS cohort in comparison 
to control cohort was assessed for each BMI sub groups.
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and mortality, which are similar to PCOS comorbidities 
(except the road traffic accidents). However, whether OSA 
increases the risk of these comorbidities in women with 
PCOS is largely unknown. A recent systematic review 
and meta-analysis showed that women with both PCOS 
and OSA are more likely to have hirsutism, hypertension, 
insulin resistance, hyperlipidaemia, and dysglycaemia 
than women with PCOS only (24). However, these 
findings were based on small-scale cross-sectional studies 
with a high risk of bias (9). Hence, longitudinal and 
interventional studies to assess the temporal relationship 
and causation are needed.
The findings of our study need to be interpreted 
within the context of the limitations. We carried out an 
observational cohort study using data from primary care 
and hence we did not have access to the results of the 
polysomnography, polygraphy or oximetry such as the 
AHI, oxygen desaturation index and other hypoxemic 
measures. In addition, since we and other studies (14, 
17) have observed a much lower prevalence of PCOS and 
OSA in electronic medical records, it is possible that many 
patients with PCOS and OSA remained undiagnosed. This 
may be due lack of diagnosis or incomplete recording 
of PCOS and OSA diagnosis in primary care setting. It is 
possible that patients with PCOS who come to the attention 
of the treating clinician represented the more severe 
phenotype which may have resulted in an overestimate 
of the effect size. This may limit the generalizability of our 
findings to patients with milder form of disease. On the 
other hand, the unexposed population may have patients 
with undiagnosed PCOS which could potentially lead to 
an underestimation of the effect size.
Nevertheless, our study has several strengths including 
the large sample size, the longitudinal nature of the study, 
the matched controlled design and the adjustment for a 
wide range of confounders including BMI. In addition, this 
was a population-based study rather than data from tertiary 
centres and hence the findings are much more generalizable. 
The longitudinal design of the study also allowed us to 
assess the predictors of OSA in women with PCOS.
We conclude that women with PCOS are at increased 
risk of developing OSA compared to women without PCOS 
independent of obesity and other potential cofounders. 
This increased risk was present in patients with normal 
weight, overweight and obesity. Clinicians treating 
women with PCOS should have a low threshold to test 
for OSA. In addition, our findings suggest that clinical 
features of hyperandrogenism and low progesterone may 
contribute to the increased risk of OSA in women with 
PCOS. Whether OSA worsens the long-term sequelae 
of PCOS and whether CPAP treatment has favourable 
impacts on women with PCOS and OSA remains to be 
examined.
Supplementary data
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